Amyloidosis

Patisiran therapy reduces ventricular myocardial strain in hereditary transthyretin amyloidosis

1. Use of patisiran, an RNA interference therapy, in patients with hereditary transthyretin (hATTR) cardiac amyloidosis was linked to reduced left ventricular global longitudinal strain (LVGLS) compared with placebo. 2. The therapy-associated reduction in ventricular myocardial strain was greatest for the basal region. The mid and apical regions of the Czytaj więcej…